Clinical trial
A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.
NCT02281344 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.
- Lead sponsor
- Medicines for Malaria Venture
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 31, 2014
- Completion date
- December 19, 2014
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.